Fig. 3: Neutralizing antibodies elicited by the top three LNP cationic lipids.
From: Lipid Nanoparticle Development for A Fluvid mRNA Vaccine Targeting Seasonal Influenza and SARS-CoV-2
A SARS-CoV-2 Virus microneutralization assay on plasma samples collected at different time points from mice immunized with unmodified spike mRNA LNPs containing top ionizable lipids (ALC0315, SM102 or DODMA). Mice (n =5 per group) received two intramuscular injections at d0 (prime) and d14 (boost). Dashed line indicates the cutoff titer of 40. B Controls. Positive, hyperimmune plasma, n = 5. Naïve, normal mouse plasma, n = 3. Statistical analysis was performed between formulation groups vs Naïve. *, p < 0.05; **, p < 0.01; ***, p < 0.001. Only significant p values are shown. nd, not determined.
